Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Minocycline Hydrochloride

FDA-approved product (capsule, oral), marketed as Amzeeq, Arestin, Dynacin and 7 more.

Registered studies
50+
Lab records
26
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Minocycline Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Conjunctivitis
  • Infection
  • Ornithosis
  • Periodontitis
  • Respiratory tract infectious disorder
  • Rosacea
  • Spotted fever

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Antiinfectives for treatment of acne; Tetracyclines
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF07; WHO ATC J01AA08

Repurposing investigation

Minocycline Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA89.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli89.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis80.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 4 of 4 lab records
  • E. coli: measured active in 3 of 3 lab records
  • K. pneumoniae: measured active in 14 of 17 lab records
  • M. tuberculosis: measured active in 2 of 2 lab records
Open Minocycline Hydrochloride in ChEMBL Registered studies below
Show the 26 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Minocycline Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Minocycline In Neurocognitive Outcomes - Sickle Cell Disease

    NCT05605366 · start 2026-12-01

    Registered record
    Registry ID
    NCT05605366
    Conditions
    Sickle Cell Disease; Cognitive Impairment; Cognitive Decline; Cognitive Change; Cognitive Dysfunction; Cognitive Deficit; Neuroinflammatory Response
    Interventions
    Minocycline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2028-06-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease; Cognitive Impairment; Cognitive Decline; Cognitive Change +3 more
    InterventionMinocycline; Placebo
    PhasePhase 1
    Registry statusNot yet recruiting

  • Topical Minocycline for CARP

    NCT07462702 · start 2026-09-15

    Registered record
    Registry ID
    NCT07462702
    Conditions
    Confluent and Reticulated Papillomatosis (CARP)
    Interventions
    Topical Minocycline Foam FXFM244; Control
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-09-15
    Completion
    2028-02
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConfluent and Reticulated Papillomatosis (CARP)
    InterventionTopical Minocycline Foam FXFM244; Control
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP)

    NCT07594301 · start 2026-05-19

    Registered record
    Registry ID
    NCT07594301
    Conditions
    Acute Ischemic Stroke; Endovascular Thrombectomy; Minocycline; Posterior Circulation; Arterial Occlusion
    Interventions
    Minocycline hydrochloride capsule; Placebo capsules of Minocycline hydrochloride capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-05-19
    Completion
    2028-12
    Enrolment
    234

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke; Endovascular Thrombectomy; Minocycline; Posterior Circulation +1 more
    InterventionMinocycline hydrochloride capsule; Placebo capsules of Minocycline hydrochloride capsules
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Fecal Molecular Susceptibility-guided Hp First-line Therapy

    NCT07405684 · start 2026-02-28

    Registered record
    Registry ID
    NCT07405684
    Conditions
    HELICOBACTER PYLORI INFECTIONS
    Interventions
    7-day fecal molecular susceptibility-guided therapy; 14-day fecal molecular susceptibility-guided therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-02-28
    Completion
    2028-12-31
    Enrolment
    544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS
    Intervention7-day fecal molecular susceptibility-guided therapy; 14-day fecal molecular susceptibility-guided therapy
    PhasePhase 4
    Registry statusNot yet recruiting

  • Minocycline in Stroke Study at Maimonides

    NCT07237048 · start 2026-02-02

    Registered record
    Registry ID
    NCT07237048
    Conditions
    Stroke; Ischemia Stroke; Hemorrhagic Strokes; Mortality; Morbidity; Cerebrovascular Accident (Stroke); Intracerebral Haemorrhage (ICH)
    Interventions
    Minocycline 200mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-02-02
    Completion
    2028-12
    Enrolment
    1,164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Ischemia Stroke; Hemorrhagic Strokes; Mortality +3 more
    InterventionMinocycline 200mg
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

    NCT06120140 · start 2024-02-16

    Registered record
    Registry ID
    NCT06120140
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Amivantamab IV; Amivantamab SC; Lazertinib; Doxycycline; Minocycline; Clindamycin; Chlorhexidine; Noncomedogenic skin moisturizer; Ruxolitinib; Tacrolimus; Zinc gluconate; Propranolol; Timolol; Clobetasol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-02-16
    Completion
    2030-06-30
    Enrolment
    305

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionAmivantamab IV; Amivantamab SC; Lazertinib; Doxycycline +10 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.

    NCT06603688 · start 2023-11-20

    Registered record
    Registry ID
    NCT06603688
    Conditions
    Helicobacter Pylori Infection; Chronic Gastritis
    Interventions
    esomeprazole; Bismuth; Amoxicillin; clarithromycin; Berberine; Minocycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-11-20
    Completion
    2024-12-01
    Enrolment
    548

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Chronic Gastritis
    Interventionesomeprazole; Bismuth; Amoxicillin; clarithromycin +2 more
    PhasePhase 4
    Registry statusUnknown

  • Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)

    NCT05512910 · start 2023-03-04

    Registered record
    Registry ID
    NCT05512910
    Conditions
    Ischemic Stroke, Acute; Minocycline; Endovascular Treatment; Basilar Artery Occlusion
    Interventions
    Minocycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2023-03-04
    Completion
    2025-06-04
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke, Acute; Minocycline; Endovascular Treatment; Basilar Artery Occlusion
    InterventionMinocycline
    PhasePhase 4
    Registry statusActive not recruiting

  • Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy

    NCT05487417 · start 2022-11-01

    Registered record
    Registry ID
    NCT05487417
    Conditions
    Ischemic Stroke, Acute
    Interventions
    Minocycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-11-01
    Completion
    2025-09-10
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke, Acute
    InterventionMinocycline
    PhasePhase 4
    Registry statusCompleted

  • Comparing the Efficacy of Metronidazole and Minocycline Gels for the Treatment of Diabetic Periodontitis Patients

    NCT06027151 · start 2022-10-06

    Registered record
    Registry ID
    NCT06027151
    Conditions
    Periodontitis; Diabetes Mellitus
    Interventions
    1ml of 1% metronidazole gel; 1ml of 2% minocycline gel; 1ml of combination of 1% metronidazole gel and 2% minocycline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-10-06
    Completion
    2023-07-31
    Enrolment
    380

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontitis; Diabetes Mellitus
    Intervention1ml of 1% metronidazole gel; 1ml of 2% minocycline gel; 1ml of combination of 1% metronidazole gel and 2% minocycline
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder

    NCT07804979 · start 2022-05-12

    Registered record
    Registry ID
    NCT07804979
    Conditions
    Major Depressive Disorder (MDD); Treatment-resistant Depression (TRD)
    Interventions
    Minocycline; Celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-05-12
    Completion
    2023-09-15
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD); Treatment-resistant Depression (TRD)
    InterventionMinocycline; Celecoxib
    PhaseNot applicable
    Registry statusCompleted

  • A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects

    NCT05452785 · start 2022-05-07

    Registered record
    Registry ID
    NCT05452785
    Conditions
    Pharmacokinetics
    Interventions
    DFD-29 (Minocycline) Fasting; DFD-29 (Minocycline) Fed; Solodyn (Minocycline) Fasting
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-05-07
    Completion
    2022-05-25
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionDFD-29 (Minocycline) Fasting; DFD-29 (Minocycline) Fed; Solodyn (Minocycline) Fasting
    PhasePhase 1
    Registry statusCompleted

  • Topical Antisepsis in Head and Neck Cancer Surgery

    NCT04721626 · start 2021-01-06

    Registered record
    Registry ID
    NCT04721626
    Conditions
    Head and Neck Cancer
    Interventions
    Chlorhexidine Gluconate; Povidone-iodine; Tetracycline Ointment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-01-06
    Completion
    2021-10-04
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    InterventionChlorhexidine Gluconate; Povidone-iodine; Tetracycline Ointment
    PhaseNot recorded
    Registry statusCompleted

  • Minocycline Treatment in Retinitis Pigmentosa

    NCT04068207 · start 2019-08-25

    Registered record
    Registry ID
    NCT04068207
    Conditions
    Retinitis Pigmentosa; Inherited Retinal Dystrophy; Retina Disorder
    Interventions
    Minocycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-08-25
    Completion
    2023-12-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinitis Pigmentosa; Inherited Retinal Dystrophy; Retina Disorder
    InterventionMinocycline
    PhasePhase 2
    Registry statusCompleted

  • Minocycline for Alcohol Use Disorder

    NCT03244592 · start 2018-01-15

    Registered record
    Registry ID
    NCT03244592
    Conditions
    Alcohol Use Disorder; Inflammation; Neurocognitive Dysfunction; Craving; Alcohol Drinking
    Interventions
    Minocycline; Sugar pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2018-01-15
    Completion
    2018-03-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder; Inflammation; Neurocognitive Dysfunction; Craving +1 more
    InterventionMinocycline; Sugar pill
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn